William Weigold, MD
Cardiovascular Disease · Washington, DCNPI 1326085531
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 175 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$594
- Novartis$471
- Pfizer$336
- Johnson & Johnson$306
- Actelion Pharmaceuticals US, Inc.$228
- AstraZeneca$209
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,90199%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 23 | $594 |
| Novartis | 24 | $471 |
| Pfizer | 16 | $336 |
| Johnson & Johnson | 13 | $306 |
| Actelion Pharmaceuticals US, Inc. | 9 | $228 |
| AstraZeneca | 9 | $209 |
| Amgen | 8 | $189 |
| Philips North America LLC | 9 | $182 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $174 |
| Novo Nordisk | 7 | $148 |
| Merck | 9 | $137 |
| Alnylam Pharmaceuticals Inc. | 5 | $135 |
| Boston Scientific | 4 | $99 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $94 |
| Atricure, Inc. | 3 | $92 |
| Bayer | 4 | $74 |
| Medicomp Inc | 3 | $68 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $53 |
| Baxter Healthcare | 1 | $45 |
| Irhythm Technologies, Inc. | 1 | $33 |
| Bridgebio Pharma, Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| Vital Connect, Inc | 1 | $21 |
| Stryker | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$230
How this compares
$3,923 in reported general payments places this provider in the 65th percentile of 105 cardiovascular disease providers in District of Columbia.
See all cardiovascular disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $146,691 |
| EntrestoSacubitril/Valsartan | 45 | $85,042 |
| XareltoRivaroxaban | 51 | $70,176 |
| Repatha SureclickEvolocumab | 13 | $8,345 |
| Olmesartan Medoxomil | 77 | $4,412 |
| Metoprolol Succinate | 195 | $3,841 |
| Atorvastatin Calcium | 206 | $3,222 |
| Rosuvastatin Calcium | 116 | $2,222 |
| Amlodipine Besylate | 133 | $1,570 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 42 | $1,502 |
| Losartan Potassium | 61 | $1,157 |
| Torsemide | 17 | $923 |
| Flecainide Acetate | 12 | $863 |
| Carvedilol | 79 | $858 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 26 | $797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $336 | $146,691103 claims |
| NovartisEntresto | $471 | $85,04245 claims |
| Johnson & JohnsonXarelto | $306 | $70,17651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 105 cardiovascular disease providers in District of Columbia.
Other cardiovascular disease in Washington
- Hayder HashimWashington$824K
- Joshua YamamotoWashington$376K
- Mardi Gomberg-MaitlandWashington$320K
- Jaffar KhanWashington$318K
- Isaac Opoku-AsareWashington$146K
- Judith HsiaWashington$65K
- Ana BaracWashington$34K
- Jonathan PlehnWashington$32K
- Andrew ChoiWashington$32K
- Felton AndersonWashington$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.